Results 241 to 250 of about 79,283 (266)

Acneiform eruptions: A common cutaneous toxicity of the MEK inhibitor trametinib

Australasian Journal of Dermatology, 2014
Georgina V Long, Richard Kefford, Pablo Uribe   +2 more
exaly  

Heterocyclyl compounds as MEK inhibitors

2013
DAVE BHAVESH, BANERJEE RAKESH KUMAR, PHUKAN SAMIRON, KHOJE ABHIJIT DATTA, HANGARGE RAJKUMAR, JADHAV JITENDRA SAMBHAJI, PALLE VENKATA P, KAMBOJ RAJENDER KUMAR   +7 more
openaire   +4 more sources

BRAF and MEK Inhibitors

2013
openaire   +1 more source

A phase II evaluation of selumetinib (AZD6244, ARRY-142886), a selective MEK-1/2 inhibitor in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study

Gynecologic Oncology, 2015
Robert L Coleman, Premal Thaker, Jacob Rotmensch   +2 more
exaly  

Overactivation of Akt Contributes to MEK Inhibitor Primary and Acquired Resistance in Colorectal Cancer Cells

Cancers, 2019
Shozo Nishida, Motohiro Imano, Tsubaki M   +2 more
exaly  

PREPARATION OF MEK INHIBITOR AND FORMULATION COMPRISING MEK INHIBITOR

2018
CHRISTOPH MAX KRELL, MARIAN MISUN, DANIEL ANDREAS NIEDERER, WERNER HEINZ PACHINGER, MARIE-CHRISTINE WOLF, DANIEL ZIMMERMANN, LIU WEIDONG, PETER J STENGEL, PAUL NICHOLS   +8 more
openaire   +1 more source

Role of the MEK Inhibitor Trametinib in the Treatment of Metastatic Melanoma

Future Oncology, 2014
exaly  

Compounds and compositions as inhibitors of MEK

2015
BOCK MARK GARY, MOEBITZ HENRIK, PANIGRAHI SUNIL KUMAR, PODDUTOORI RAMULU, SAMAJDAR SUSANTA   +4 more
openaire   +6 more sources

BRAF/MEK inhibitors

Reactions Weekly
openaire   +1 more source

Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation

Oncologist
Miles A Miller, , Jeffrey Heier
exaly